Free Trial
NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.77
$3.99
52-Week Range
N/A
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADMP stock logo

About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

ADMP Stock News Headlines

DMK Pharmaceuticals Corp DMK
Adamis Pharmaceuticals (NASDAQ: ADMP)
Q1 2023 Adamis Pharmaceuticals Corp Earnings Call
See More Headlines
Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2022
Today
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMP
Fax
N/A
Employees
11
Year Founded
2006

Profitability

Net Income
$-26,480,000.00
Net Margins
-502.73%
Pretax Margin
-471.80%

Debt

Sales & Book Value

Annual Sales
$4.76 million
Book Value
($1.26) per share

Miscellaneous

Free Float
9,237,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
1.27

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. David J. Marguglio (Age 53)
    Co-Founder, Interim CFO. Pres & COO
    Comp: $526.35k
  • Dr. Ebrahim Versi M.D. (Age 70)
    Ph.D., CEO & Chair of the Board
  • Ms. Jennifer C. Suski
    Sr. Director of Marketing
  • Mr. Eddie Wabern Glover (Age 73)
    Chief Exec. Officer of US Compounding Inc
  • Mr. Robert B. Rothermel (Age 79)
    Consultant

ADMP Stock Analysis - Frequently Asked Questions

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 420.53% and a negative net margin of 502.73%. During the same period last year, the firm posted ($11.20) earnings per share.

When did Adamis Pharmaceuticals' stock split?

Adamis Pharmaceuticals's stock reverse split on the morning of Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

This page (NASDAQ:ADMP) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners